Commercial dependence on LUPKYNIS
Aurinia’s revenue and cash generation are concentrated in one marketed product, so any slowdown in uptake or access would have an outsized impact.
- Scope
- U.S. lupus nephritis market
- Materiality
- high
Aurinia Pharmaceuticals Inc.
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company focused on autoimmune diseases with high unmet medical need. Its commercial business is centered on LUPKYNIS (voclosporin), the first FDA-approved oral therapy for adult patients with active lupus nephritis. The company also has a development-stage pipeline asset, aritinercept, a dual BAFF/APRIL inhibitor being studied for autoimmune diseases. Aurinia sells directly in the U.S. through specialty pharmacies and a specialty distributor, while also monetizing ex-U.S. markets through its collaboration with Otsuka.
43,9 %
88,5 %
101,5 %
+20,4 %
5.25
4.76
| % | |
|---|---|
| Commercial product sales | 91% Net sales of LUPKYNIS in the U.S. through specialty pharmacies and a specialty distributor. |
| Collaboration and royalty revenue | 4% Milestones, royalties, and licensing income from the Otsuka agreement for ex-U.S. markets. |
| Commercial supply services | 5% Manufacturing and supply services provided to Otsuka, including use of the Monoplant capacity. |
| Pipeline development | 0% Research and development activity for aritinercept and other autoimmune disease opportunities. |
Aurinia’s direct commercial customers are two specialty pharmacies and one specialty distributor in the United States...
- U.S. specialty pharmaciesprimary
Buy LUPKYNIS for dispensing to patients with active lupus nephritis and are critical to prescription fulfillment and inventory management.
- U.S. specialty distributorprimary
Purchases and distributes LUPKYNIS in the U.S. channel, supporting access and supply continuity.
- Otsuka Pharmaceuticalprimary
Buys voclosporin inventory and commercializes it in Japan, Europe, the U.K., Switzerland and other territories under the collaboration.
- Patients with lupus nephritisprimary
The end users of LUPKYNIS; demand depends on diagnosis, prescribing behavior, and treatment adoption.
- Autoimmune disease research and development partnersemerging
Future partners or collaborators may support development and commercialization of aritinercept or other assets.
Aurinia is incorporated in Alberta, Canada, but its commercial revenue is heavily tied to the United States, where...
- •Headquartered in Edmonton, Alberta, Canada
- •U.S. is the core commercial market for LUPKYNIS
- •Otsuka Territories include Japan, EU, U.K., Switzerland and others
- •Supply chain imports into the U.S. primarily from Switzerland
- •Cross-border commercialization creates tariff and trade-policy exposure
- •Ex-U.S. revenue is tied to partner execution rather than direct sales
Aurinia’s near-term strategy is to expand LUPKYNIS penetration in lupus nephritis, which remains the company’s main...
01
Expand LUPKYNIS penetration in lupus nephritisshort-term
The company is substantially dependent on one commercial product, so deeper adoption is the main driver of growth and cash generation.
02
Strengthen ex-U.S. monetization through Otsukamedium-term
The collaboration provides royalties, milestones, and supply revenue without requiring Aurinia to build direct international infrastructure.
03
Secure manufacturing and supply continuityshort-term
Commercial success depends on uninterrupted cGMP-compliant supply from contract manufacturers.
04
Advance aritinercept as a second autoimmune assetlong-term
A successful pipeline program could diversify revenue and reduce single-product dependence.
Aurinia is highly exposed to the commercial performance of LUPKYNIS, so slower-than-expected uptake, competitive...
Supply chain interruption
The company relies on sole-source contract manufacturers and third parties for API, drug product, and distribution services.
- Scope
- Manufacturing and logistics
- Materiality
- high
Patent and generic challenge risk
ANDA filings and patent litigation could shorten effective exclusivity if claims are invalidated or not infringed.
- Scope
- LUPKYNIS exclusivity
- Materiality
- high
Trade and tariff policy risk
The company imports certain products primarily from Switzerland and sells into Otsuka territories, making it vulnerable to policy changes and retaliatory tariffs.
- Scope
- U.S. and international trade flows
- Materiality
- medium
Pipeline development risk
Aritinercept is still in development and may not achieve clinical or regulatory success.
- Scope
- R&D pipeline
- Materiality
- medium
Revenue recognition for product sales and collaboration revenue
Can cause large quarter-to-quarter swings in revenue mix
Milestone revenue recognition
Makes year-over-year collaboration revenue less predictable
Monoplant lease accounting
Impacts gross margin and operating leverage
Inventory and channel estimates
Can affect revenue timing and reserve estimates
Kiniksa Pharmaceuticals International, plc
KNSA · Pharmaceutical Preparations
Kiniksa Pharmaceuticals International, plc is a biopharmaceutical company focused on developing and commercializing therapies for diseases with unmet medical…
Akebia Therapeutics, Inc.
AKBA · Pharmaceutical Preparations
Akebia Therapeutics is a U.S.-based biopharmaceutical company focused on kidney disease, with two commercial products and a pipeline aimed at rare kidney diseases and other renal-related indications.
Oruka Therapeutics, Inc.
ORKA · Pharmaceutical Preparations
Kyverna Therapeutics, Inc.
KYTX · Biological Products, (No Diagnostic Substances)
Kyverna Therapeutics is a clinical-stage biopharmaceutical company developing cell therapies for autoimmune diseases.
Aclaris Therapeutics, Inc.
ACRS · Pharmaceutical Preparations
Aclaris Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing small and large molecule therapies for immuno-inflammatory diseases.
ARVINAS, INC.
ARVN · Pharmaceutical Preparations
: 11/08/2026